Robert Roe talks to Antonio Peña EPEEC, project coordinator and senior researcher for the Barcelona Supercomputing Center about progress on a European programming framework for HPC
The Barcelona Supercomputing Centre has announced that the MareNostrum 4 supercomputer now has three operational racks of IBM Power 9 servers in its production system. The new servers deliver with a peak performance of 1.5 petaflops
In the 16th PRACE Call for Project Access, Spain has allocated 470 million core hours on the MareNostrum supercomputer to 17 projects led by scientists from different European countries
Research carried out Barcelona Supercomputing Center (BSC) which reanalysed public genetic data using innovative computational methods has enabled the identification of new genetic markers associated with an increased risk to develop Type 2 Diabetes (T2D)
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
